Information, Community and Research Funding
The mission of The EHE Foundation is to seek treatments and a cure for Epithelioid Hemangioendothelioma (EHE) by increasing awareness, pursuing scientific research, advocating for and supporting EHE patients, and bridging information between researchers, providers and patients.
HOW TO FIGHT EHE
Giving Tuesday is Upon Us!
Tuesday, November 27, 2018
During this past week, we have featured several touching stories of those affected by EHE (see below). These stories have one thing in common, which all EHE patients can relate to: there are no standard treatments for EHE. Money raised by The EHE Foundation during #Giving Tuesday (Nov 27th) will address this common issue and give doctors of EHE patients options for evidence-based treatments.
We are planning a multi institutional international project. EHE is highly unpredictable and exhibits a broad variety of clinical behaviors, so we must include as many EHE patients as possible to obtain reliable information. The math is simple: amount of funding we have for this study = more hospitals will participate = more EHE cases will be included = data obtained will be more comprehensive and accurate.
The main goal of the study is to assess:
- Local and systemic treatment modalities applied to EHE across various EHE locations and response to these treatments
- Difference in progression between interventional treatment and “wait and watch” approach • Clinical and radiological presentations indicative of EHE progression
- Utilized symptoms management and the impact on quality of life
Would you like a simple way to help explain what we do here at The EHE Foundation? Feel free to use this bifold. You can click the images below to enlarge and print it to share with those not online. Remember, your donation will be DOUBLED on #GivingTuesday (Nov 27th)! "
#GivingTuesday is a global movement to celebrate and encourage giving after Thanksgiving, Black Friday, and Cyber Monday. We are thrilled to announce that donations to The EHE Foundation will be DOUBLED on #GivingTuesday (Tues, Nov 27th) by our generous supporters. This is your chance to double your impact in helping those affected by this extremely rare cancer by hitting the “donate now” button on this page, donating through our Facebook Page, or by sending a check to The EHE Foundation, 1561 Hopi Ct, Hobart, WI 54313.
Donations could also be TRIPLED if done through Facebook early on #GivingTuesday before the $7 million dollar matching from Facebook and PayPal is reached. Matching will start at 8:00am EST (5:00am PST) on Tues, Nov 27, 2018. Donations up to $250k per nonprofit and $20k per donor are eligible to be matched, so $7 million won’t last long!
Donations could be QUADRUPLED! Many companies match employee donations dollar for dollar, and some will even double or triple gift amounts. Check with your employer for the chance to have an even greater impact with your donation. You can trust that your contribution will go a long way in continuing our forward momentum in research for EHE. We know you have many options when it comes to giving, but we hope you will support those affected by EHE.
FACES OF EHE
Leading up to #GivingTuesday (Nov 27th), we will feature a new “Faces behind EHE”each day. We want you to meet some of the extraordinary people behind this unpredictable and often fatal cancer. On #GivingTuesday, your donation to The EHE Foundation will be doubled!
“My name is Jennifer San. I was first diagnosed with EHE in Dec 2017 after having a biopsy on two tumors that were removed from part of my left lung. I’ll never forget the day and the look on the doctor’s face when he gave me the news. When he opened the door to the room I knew by the look on his face the news wasn’t going to be good. His exact words were “All along I thought you had a rare tumor, but I wasn’t expecting you to have an even rare form of cancer”. The nurse came…
Read MoreIMPORTANT EHE NEWS & TRIALS
The Pledge, Edition 14
We warmly welcome all our readers to this fourteenth edition of “The Pledge”, the quarterly newsletter of the EHE Group. We hope you enjoy this newsletter, covering the third quarter of 2018.
Trametinib Trial
Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery.
ClinicalTrials.gov Identifier: NCT03148275
For the last several years Dr.Brian Rubin has been working on unlocking genetic driving mechanism behind EHE progression. His work resulted in identification of a pathway directly involved in supporting of EHE genetic malfunction. During the Lab experiments, Dr Rubin was able to disrupt this pathway with MEK inhibitor.
The clinical trial uses MEK inhibitor Mekinist. The purpose of the study to verify that what Dr.Rubin observed in his Lab actually translates in clinical effect in EHE patients. It is a multi institutional study which makes it very easy for enrollment in different parts of the country. You can see more information using following link.
https://clinicaltrials.gov/ct2/show/NCT03148275
|
FAQs for P10015, SARC033 – Phase II trial of trametinib in patients with unresectable or metastatic epithelioid hemangioendothelioma (EHE). Is there a point at ...
|
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
ClinicalTrials.gov Identifier: NCT03331250
This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE).
-The drug involved in this study is Eribulin
In this research study, the investigators are studying how safe and effective eribulin is in participants with Angiosarcoma or EHE.
Eribulin was created to mimic the structure of a chemical that is released from a sea sponge. The investigators believe that this drug has anti-cancer effects on tumors by blocking proteins called microtubules, among other functions. It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die similar to other drugs that target microtubules